The United States ruling class is close to reaching a deal with Moderna to fund the bird flu “vaccine” trial. The big pharma controllers and ruling class are both insisting that if/when this virus jumps to humans, the vaccine already created will be good enough to handle the mutation.

Is this the next scamdemic?

SCRIPTED: New Human Vaccines Are Already Developed & Stockpiled For Pandemic Flu That Doesn’t Exist Yet

It’s starting to look that way, that’s for sure. Most mainstream media outlets are already discussing how the rulers will “deploy” the new “vaccines” and make sure the slave class is injected.

Greg Mannarino: Scamdemic 2.0 Is Ready! Deployment of A New Vaxx Soon!

According to a report by Reuters, federal funding from the Biomedical Advanced Research and Development Authority (BARDA) could come as soon as next month and would include a promise to procure doses if late-stage trials are successful, the FT report said, citing people close to the discussions.

Moderna is testing the experimental shot, mRNA-1018, against several strains of the virus – including the currently circulating H5N1 variant. It said dosing in an early-to-mid-stage study of the vaccine was completed, and it expects data soon.

The U.S. government is manufacturing about 4.8 million doses of CSL Seqirus’ (CSL.AX)  bird flu vaccine. It is also in “active conversations” with Pfizer (PFE.N), and Moderna on a potential mRNA vaccine.

Last week, the ruling class told the peasants that another human had been infected with the H5N1 bird flu virus after being exposed to dairy cattle.

H5N1 Bird Flu Has Mutated

This shouldn’t be a surprise that once again, the rulers intend to fund these shots. That means, that they intend to make it as easy as possible for the American human cattle to rush out and get injected with yet another mRNA substance.

COVID-19 mRNA Shots Are Legally Not Vaccines

Unsurprisingly, shares of Moderna have risen about 40% since April 1, when the second known human case of bird flu in the United States was reported. The stock was up about 3% at $151.25 in premarket trading on Thursday.